Precisely targeting the interface between
innate and adaptive immunity.

Dr. Kiener is currently Chief Scientific Officer of Ambrx.  Dr. Kiener's most recent position was CEO of Zyngenia.  Prior to that, Dr. Kiener was at AstraZeneca PLC/MedImmune, LLC as executive vice president and global head of biologics R&D.  During eight years at MedImmune as Executive Vice President and Head of Research and Development, Dr. Kiener helped build industry-leading protein and antibody engineering capabilities and oversaw the submission of multiple INDs and NDAs. 


Dr. Kiener was also responsible for the integration of both the protein/antibody engineering company Cambridge Antibody Technology and the B-cell biologics company Cellective Therapeutics into MedImmune. Prior to working at MedImmune, he spent 18 years at Bristol-Myers Squibb, ten of which were spent working on biological therapeutics.


During his tenure at MedImmune, Dr Kiener was also a member of the MedImmune Ventures investment committee and was actively involved in growing the organization’s venture portfolio. Dr. Kiener previously served on three boards of directors: Receptor Biologix, Synovex Inc. and Virdante Pharmaceuticals. He currently serves on the scientific advisory boards of KAI, Genocea, NKT Therapeutics and VLST Inc.  Dr. Kiener received his B.A. in Chemistry from the University of Lancaster, UK, and his D. Phil. in Biochemistry from Oxford University, UK .  Dr. Kiener has published more than 100 papers in peer-reviewed journals, and is an inventor on more than 20 patents and patent applications.